{
  "pmcid": "5647649",
  "sha256": "3ea0df261d889febc5b20b6add8231304e904df5d49899e9778a57fa592fb40c",
  "timestamp_utc": "2025-11-09T22:47:26.558840+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.984850166481689,
    "reading_ease": 24.179239733629316,
    "word_count": 212
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Preoperative and Postoperative Imatinib in Gastrointestinal Stromal Tumor (GIST) Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Nineteen patients were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible patients had histologically confirmed kit-expressing GIST ≥ 1 cm, untreated with chemotherapy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Nineteen patients were randomised to receive 3, 5, or 7 days of preoperative imatinib (300 mg twice daily) and 2 years of postoperative imatinib (600 mg daily)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety and efficacy of preoperative and postoperative imatinib in GIST patients undergoing surgical resection."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was tumor cell apoptosis, measured postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed by the institutional department of biostatistics, with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Nineteen patients were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Nineteen patients were randomised, and 17 were analysed."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Tumor cell apoptosis increased by an average of 12% (p = 0.04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar to an imatinib-naïve cohort (p ≥ 0.1)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: No funding source influenced the study."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}